Q. Ni

发表

PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3

Lin Qiu, D. Xie, Hui-Jun Cao, 2022, Oncogene.

Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase 2 trial.

Kang Wang, Jie Shi, Wei-xing Guo, 2022, Future oncology.

hPCL3s Promotes Hepatocellular Carcinoma Metastasis by Activating β-Catenin Signaling.

Hao Jiang, D. Xie, Xiao-yan Zhou, 2018, Cancer research.

ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2

Lin Qiu, D. Xie, Hui-Jun Cao, 2022, Cell Death & Differentiation.

Age-related ceRNA networks and the mRNA/protein correlation in Drosophila ageing

Y. Li, Y. Yuan, D. Li, 2021 .

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1

D. Xie, Xiao-Fan Wang, F. Yin, 2022, Advanced science.

Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis

D. Xie, Hui-Jun Cao, Kang Wang, 2021, Oncogene.

Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis

Lin Qiu, D. Xie, Hui-Jun Cao, 2020, Proceedings of the National Academy of Sciences.

Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of β‐catenin/TCF/LEF signalling

D. Xie, F. Yin, Hui-Jun Cao, 2019, Cell proliferation.

Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma

Lin Qiu, D. Xie, Hui-Jun Cao, 2022, Cellular and Molecular Gastroenterology and Hepatology.

Epithelial V‐like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB‐PI3K‐AKT pathway

D. Xie, Shuqun Cheng, Xingyuan Ma, 2020, Cancer science.

CHML promotes liver cancer metastasis by facilitating Rab14 recycle

Lin Qiu, D. Xie, Xiao-Fan Wang, 2019, Nature Communications.

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study

W. Lau, Wei-Wei Pan, Kang Wang, 2023, Frontiers in Immunology.

Ochratoxin A Induces Steatosis via PPARγ-CD36 Axis

D. Xie, Dianzhen Yu, Hui-Jun Cao, 2021, Toxins.

BMP10 suppresses hepatocellular carcinoma progression via PTPRS–STAT3 axis

D. Xie, F. Yin, Kang Wang, 2019, Oncogene.

Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer

D. Xie, Xingyuan Ma, Jingjing Li, 2019, Oncology letters.

CHML promotes liver cancer metastasis by facilitating Rab14 recycle

D. Xie, Xiao-Fan Wang, Lin Qiu, 2019, Nature Communications.

Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial.

Jie Shi, J. Zhai, Kang Wang, 2023, Future oncology.

Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study

Wei-Wei Pan, Kang Wang, Jie Shi, 2023, Therapeutic advances in gastroenterology.

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Lin Qiu, D. Xie, Xiao-Fan Wang, 2021, Nature Communications.

PPDPF suppresses the development of hepatocellular carcinoma through TRIM21-mediated ubiquitination of RIPK1.

D. Xie, Hui-Jun Cao, Kang Wang, 2023, Cell reports.

PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3

Lin Qiu, D. Xie, Hui-Jun Cao, 2022, Oncogene.

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation

Kang Wang, Yuqiang Cheng, Jin-Kai Feng, 2023, BMC Cancer.